Clinical trial

Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy…

NCT00110279 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00110279
Title Safety of and Immune Response to a Bird Flu Virus Vaccine (H9N2) in Healthy Adults (Study A)
Official title Phase I Inpatient Study of the Safety and Immunogenicity of H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Avian Influenza H9N2 Infection in the Event of a Pandemic (Study A)
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Collaborators Johns Hopkins Bloomberg School of Public Health
Status Completed
Phase Phase 1
Study type Interventional
Conditions Influenza, Virus Diseases
Intervention type Biological
Interventions H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)
Enrollment 30
Start date Jun 1, 2005
Primary completion Sep 1, 2005
Completion Sep 1, 2005
First posted May 6, 2005
Last update posted Jan 21, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies